



PTO/SB/21 (01-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/806,110	
	Filing Date	August 31, 2001	
	First Named Inventor	Karpalis	
	Art Unit	1632	
	Examiner Name	R. Shukla	
Total Number of Pages in This Submission	3	Attorney Docket Number	SWA-006US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<div>RECEIVED SEP 25 2003 TECH CENTER 1600/2200</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Wayne A. Keown, Ph.D. (Reg. No. 33,923)
Signature	<i>W A Keown</i>
Date	9/17/03

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail addressed to: Commissioner for Patents, P.O. BOX 1450, Alexandria, VA 22313-1450 on <u>9/17/03</u>	
Typed or printed	<i>Melanie Legare</i>
Signature	<i>Melanie Legare</i>
Date	9/17/03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

- 1-6. Cancelled.
7. (Original) A method for the treatment of metabolic bone diseases, which comprises modulating PTH and PTHrP levels that regulate osteoblast activity in a patient to modulate bone breakdown and bone formation.
8. (Currently Amended) The method of claim 7, wherein said metabolic bone diseases is ostemalacia, osteoporosis, osteopetrosis or Paget's disease.
9. (Original) Use of a compound for the modulation of PTH and PTHrP levels that regulate osteoblast activity for the treatment of metabolic bone diseases.
10. (Original) The use of claim 9, wherein said metabolic bone diseases is ostemalacia, osteoporosis, osteopetrosis or Paget's disease.
- 11-19. Cancelled.

US 098115090RP1



Creation date: 10-07-2003  
Indexing Officer: ALIEU - ANDY LIEU  
Team: 1600PrintWorkingFolder  
Dossier: 09811509

Legal Date: 09-03-2003

No.	Doccode	Number of pages
1	A...	3
2	CLM	3
3	REM	2

Total number of pages: 8

Remarks:

Order of re-scan issued on .....